New research suggests that diabetes and weight-loss drugs known as GLP-1 receptor agonists may also help treat alcohol and drug addiction. A widely used group of medications originally developed to ...

A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug ...

The excessive and uncontrolled consumption of alcohol, which can culminate in the development of alcohol use disorder or ...

A new study published Thursday found that groundbreaking weight loss and diabetes medications also combat opioid-use disorder and alcohol misuse disorder. This is the second study this fall to suggest ...

A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcohol effects, a new study suggests. Glucagon-like peptide-1 receptor (GLP-1) agonists — which contain either semaglutide or liraglutide ...

A new study by researchers at the Case Western Reserve University School of Medicine reveals that the popular diabetes and weight-loss drugs Wegovy and Ozempic are linked to reduced incidence and ...

This time, more research is showing that they may significantly curb addictive behaviors. Drugs such as Novo Nordisk's highly popular diabetes injection Ozempic can cut drug and alcohol abuse by ...

The blockbuster drugs designed to control diabetes — now also widely used to help overweight people shed pounds — show great promise for tackling other prickly health problems: treating alcoholism, ...

Drugs such as Novo Nordisk’s blockbuster Ozempic can cut drug and alcohol abuse by up to 50% according to a new study, adding to mounting evidence that the drugs yield health benefits beyond diabetes ...

Serious liver disease is becoming more common among Americans who drink heavily, according to a recent study from Keck ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Yet another ...